- ￥600 - 1699
- Sino Biological
- 50389-T26
- 北京
- 2025年09月11日
- ELISA,IHC-P,ICC/IF
- Rabbit
- Mouse
企业认证
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 抗体名：
CD8/CD8 alpha/Leu-2 Antibody, Rabbit PAb, Antigen Affinity Purified
- 抗体英文名：
CD8/CD8 alpha/Leu-2 Antibody, Rabbit PAb, Antigen Affinity Purified
- 靶点：
CD8A
- 浓度：
ELISA: 1:5000-1:10000;IHC-P: 1:500-1:2000;ICC/IF: 1:300-1:10000;
- 应用范围：
ELISA,IHC-P,ICC/IF
- 宿主：
Rabbit
- 适应物种：
Mouse
- 保质期：
12个月
- 抗原来源：
50389-M08H
- 目录编号：
50389-T26
- 级别：
免疫学试剂
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 克隆性：
兔多抗
- 保存条件：
-20℃ to -80℃
- 形态：
液体
- 亚型：
Rabbit IgG
- 免疫原：
Recombinant Mouse CD8/CD8 alpha/Leu-2 Protein (Catalog#50389-M08H)
- 规格：
20 µL/100 µL
| 规格： | 20 µL | 产品价格： | ￥600.0 |
|---|---|---|---|
| 规格： | 100 µL | 产品价格： | ￥1699.0 |
CD8/CD8 alpha/Leu-2 兔多抗（产品说明）
抗体种属：Mouse
抗体靶点：CD8A
抗体应用：ELISA,IHC-P,ICC/IF
抗原货号：50389-M08H
抗原描述：Recombinant Mouse CD8/CD8 alpha/Leu-2 Protein (Catalog#50389-M08H)
抗体宿主：Rabbit
抗体Ig类型：Rabbit IgG
抗体纯化方法：Protein A & Antigen Affinity
抗体制备：Produced in rabbits immunized with purified, recombinant Mouse CD8/CD8 alpha/Leu-2 (rM CD8/CD8 alpha/Leu-2; Catalog#50389-M08H; NP_001074579.1; Met1-Tyr196). CD8/CD8 alpha/Leu-2 specific IgG was purified by Mouse CD8/CD8 alpha/Leu-2 affinity chromatography.
抗体特异性：Mouse CD8/CD8 alpha/Leu-2
抗体保存：This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验1, Xing Y, et al. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.Acta pharmacologica Sinica, PubMed ID: 35082394
2, Huang CP, et al. Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models.Cancer letters, PubMed ID: 35902043
3, Hu Y, et al. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression.Cancer letters, PubMed ID: 35985510
4, Che YJ, et al. Lymph Node Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long-Term Survival After Heart Transplantation.Advanced materials (Deerfield Beach, Fla.), PubMed ID: 36314402
5, Pei JP, et al. AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage.Acta pharmacologica Sinica, PubMed ID: 36650292
6, Huang CP, et al. Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.American journal of cancer research, PubMed ID: 37424801
7, Liu J, et al. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.Cellular oncology (Dordrecht), PubMed ID: 37856075
8, Zhang Y, et al. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.Oncogene, PubMed ID: 38191673
技术资料暂无技术资料 索取技术资料
